...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs and aging >Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.
【24h】

Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.

机译：心血管疾病患者的前列腺增生的治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pharmacological management is the most common therapeutic approach for patients with benign prostatic hyperplasia and alpha-adrenoceptor antagonists are the most commonly prescribed initial treatment. Although all of the alpha-adrenoceptor antagonists produce similar improvements in symptom scores and urinary flow rates, they have different adverse effect profiles, especially with respect to the cardiovascular system. The older alpha-adrenoceptor antagonists, terazosin and doxazosin, were initially approved for the treatment of hypertension and are associated with higher rates of dizziness, syncope and hypotension than the newer agents, tamsulosin and alfuzosin. The older alpha-adrenoceptor antagonists are also involved in more interactions and have a greater number of precautions concerning their usage with other cardiovascular medications. Of the newer alpha-adrenoceptor antagonists, tamsulosin has a lower rate of dizziness than alfuzosin. However, both of these agents are superior to doxazosin and terazosin in that no dose escalation or titration is needed for them.
机译：对于前列腺增生的患者，药理管理是最常见的治疗方法，而α-肾上腺素受体拮抗剂是最常用的初始治疗方法。尽管所有的α-肾上腺素能受体拮抗剂在症状评分和尿流率方面均产生相似的改善，但它们具有不同的不良反应，尤其是在心血管系统方面。较早的α-肾上腺素受体拮抗剂特拉唑嗪和多沙唑嗪最初被批准用于治疗高血压，并且与较新的药物坦索罗辛和阿夫唑嗪相比，头晕，晕厥和低血压发生率更高。较老的α-肾上腺素受体拮抗剂也参与更多的相互作用，并且在与其他心血管药物一起使用时有更多的预防措施。在新型的α-肾上腺素受体拮抗剂中，坦索罗辛的头晕率低于阿夫唑嗪。但是，这两种药物都优于多沙唑嗪和特拉唑嗪，因为它们不需要剂量递增或滴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号